Fresh coverage on the economy, markets, and the forces moving money.
GLP-1 receptor agonists convert a diffuse obesity cost pool into a concentrated pharmaceutical revenue stream controlled by a highly constrained manufacturing duopoly.
The transition of obesity into a pharmacologically treated chronic condition forces an immediate collision between mass-market demand and specialty-drug pricing.
Novo Nordisk and Eli Lilly control the GLP-1 market through a physical ceiling on sterile fill-finish capacity, forcing competitors out and driving billions into vertical integration.
Eli Lilly and Novo Nordisk navigate a $200 billion incretin market through divergent capital allocation strategies prioritizing domestic manufacturing and acquisitive capacity integration.
Eli Lilly seized control of the weight-loss market with its dual-agonist tirzepatide, pushing its US market share toward 60% and driving the company to a $1 trillion market capitalization.
Physical limits in peptide synthesis and sterile fill-finish operations place a hard ceiling on near-term revenue growth for the prevailing pharmaceutical duopoly.
The market is pricing linear adoption, yet real-world persistence and payer limits make GLP-1 economics a churn-driven reallocation of healthcare dollars.
Markets must price a restrictive but not recessionary regime, where credit tightens, refinancing costs rise, and cheap money no longer anchors multiples.
Money now carries a real cost because inflation stays above target and growth is still resilient enough to keep policy restrictive.
Cheap leverage is ending as higher funding costs, balance sheet runoff, and positive term premiums reset valuations across credit and duration markets.
The economy is still repricing the end of zero rates, as higher capital costs work through debt, valuations, and policy assumptions built for cheap money.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce non dolor a magna ultrices suscipit. Suspendisse viverra lacus id lacus accumsan, aliquet fringilla nibh aliquet.
